Having 60 starters in the trial is a reasonable number, to get an indication of its effectiveness especially with information gained from the bio markers. The delay and possible additional research may enhance a positive result. As a guess this article was formulated by Kempler not David Stamler because of the lack, of additional information shareholders would appreciate.
Ann: Expanded ATH434 Phase 2 Clinical Development Program, page-10
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
-0.001(10.0%) |
Mkt cap ! $23.60M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $17.8K | 3.6M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 66 | 75025101 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 27379258 | 24 |
View Market Depth
| Last trade - 10.32am 27/06/2024 (20 minute delay) ? |
| ATH (ASX) Chart |